For monitoring patients who have been diagnosed with cancer, or have taken anti-cancer therapy, or are in remission
What is Exacta?
Exacta is a comprehensive analysis of molecular-genetic characteristics of solid tumours based on the results of several clinical studies. Especially for rare solid tumours where no guidelines are available, in the advanced situation or for tumours that are difficult to treat, exacta is providing an advantage. exacta analyses millions of data points at the molecular level to identify all relevant targets for an individual therapy.
Exacta is a comprehensive in depth tumour gene expression analysis. It analyses 100’s of millions of data points at the molecular level to reveal all possible targets for precision drugs.
Еxacta helps unravel driver mutations and pathways that are propelling a person’s cancer through multi-analyte and multi-coordinate analysis over 20.805 genes in the cancer genome. This analysis helps identify drugs that would be most effective for a particular solid tumour. Еxacta, thus enables a highly sophisticated treatment strategy beyond conventional perspective, even for difficult to treat or late stage cancers.
Most Optimal Targeted Therapy Selection:
Exacta identifies possible molecular targets and cell cycle pathways to find the most appropriate molecular targets for targeted therapy.
All relevant biomarkers for targeted therapy selection, including mutations, deletions, gene rearrangement, gene amplification / expression, are analysed.
Assessment of adverse drug reactions:
Selection of therapy with least side effects based on analysis of germline.
EXACTA е най-оптималният избор при цитотоксична терапия:
Cytotoxic drug response / resistance of cancer genome, based on DNA and gene expression.
Comprehensive exacta includes chemosensitivity testing for cytotoxic drug efficacy prediction.
What is Chemo-scale?
Изследването идентифицира лекарствата, които имат най-висок потенциал на действие за ефективно определяне на най-добрата химиотерапия за пациента. Изследва се Ин витро химиочувствителността на циркулиращи туморни клетки (CTCs) от периферна кръв за оценка на отговора към различни химиотерапевтични лекарства. Подходящо е за всички пациенти, на които се препоръчва химиотерапия на всеки етап от заболяването.
The conventional ‘Standard of Care’ approach does not take into consideration the overall architecture of a particular patient‘s tumour and consequently, patients could suffer due to failed therapies or aggressive relapse. It is, thus, imperative that the characteristics of the tumour are studied comprehensively before deciding the treatment plan, which has to be personalised to individual patients and their disease
Chemo-scale is an analysis of tumour cells to provide drug efficacy and resistance guidance for chemotherapy.
With chemo-scale analysis, we minimise the risks of therapy failure for the patient - saving money, reducing 'trail and error' and most importantly, intensifying the attack on the patient's cancer, not the patient.
Chemo-scale directly tests the effect of chemotherapy / anti-cancer drugs on the patient's tumour cells. It helps to customise the treatment plan according to sensitivity and resistance patterns of tumour cells.
With this information, the physician and the patient can choose the most effective chemotherapy from the available options.
chemo-scale is perfomed on cells taken from a fresh biopsy sample of the tumour or circulating tumour associated cells (C-ETACs) isolated from peripheral blood. A control analysis is included.
Analysing the chemosensitivity pattern of circulating tumour associated cells and tumour tissue derived cells of the same patient, we observed a concordance of 93.7%.
What is celldx?
The test represents an in-depth definition of the genome, very useful because the efficacy of targeted therapies/immunotherapies depends on the molecular changes in the tumor. Paraffin blocks are analyzed by powerful NGS (next generation sequencing technology) analysis along with immunohistochemistry. It is used in cases where there is a diagnosed cancer and there is a hurdle for molecular profiling of the tumor to explore targeted/immunotherapies.
Celldx provides deep molecular analysis for patients with advanced cancer.
Cancer follow-up by analysis of circulating tumor DNA (ctDNA). ctDNA from patient peripheral blood was analyzed for qualitative and quantitative changes in target genes. The goal is to track the tumor at the molecular level to detect recurrence at an early stage. Recommended for cancer patients who have been treated and need to be monitored for treatment effect or recurrence.
Cancertrack™ evaluates circulating tumor analytes including DNA, RNA and CTCs, which are known to be present ubiquitously in blood samples in all solid tumors.
Cancertrack can be used to monitor the disease / recurrence or changes in the tumour characteristics, as often as necessary.
Multi-coordinate and multidimensional probes to track down DNA / RNA released by cancer cells in the patient’s blood
Unique, unprecedented capability to detect cancerous activity
Enables real-time rapid response to the dynamic molecular proﬁle of a patient’s cancer
Safe, simple and cost-effective
Rapid lab result
Tests all active disease sites
Limits of detection is 0.1% Mutant Allele Frequency
The US Food and Drug Administration (FDA) has declared Datar Cancer Genetics' tests a breakthrough in medical technology of special significance.
Your doctor will explain the preparation process before taking a blood sample for the test, but please note that you should wait 24 hours after chemotherapy and also be 10 days away from your last blood transfusion.